Clinical Trial Update: Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of filgotinib and lanraplenib in females with moderately-to-severely active cutaneous lupus erythematosus completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus

Drugs mentioned

• Filgotinib (filgotinib)
• lanraplenib (lanraplenib)

Snippet

Sponsor: Gilead Sciences | Conditions: Cutaneous Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2020-04-08